Elizabeth M. Jaffee, MD, will become president of American Association for Cancer Research next month.
Jaffee is deputy director of Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, as well as associate director of Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins.
Investors got big returns on the initial sale and could see millions more over the coming years, as Harpoon’s device continues on the path to U.S. regulatory approval.
Tampa Bay Lightning owner and developer Jeff Vinik is investing $12 million in Dreamit, an early-stage venture fund and startup accelerator with offices in New York, Philadelphia and — in the foreseeable future — Tampa.
Do you find it nearly impossible to resist the opportunity to devour a cupcake, brownie, or doughnut? You’re not alone. Most of us jump at the chance to satisfy our sweet tooth, even though we know it isn’t good for us. Too many people, however, take an all-or-nothing approach when it comes to junk food, which can make it hard to quit. You don’t have to stop eating sugar completely, but eating less of it could improve and even save your life.
If you’ve been to the hospital recently, you’ve probably noticed that the hospital relies on nurses in order to keep everything running smoothly. In fact, according to the United States Bureau of Labor Statistics, there are over 3.1 million nurses in the United States alone.
This spring, the National Institutes of Health will start recruiting participants for one of the most ambitious medical projects ever envisioned.
Tweeting has long posed a dilemma for scientists. There’s abundant evidence that widely sharing a research finding in just one or two simple sentences greatly increases its use and effectiveness.
Baltimore medical device firm Perceptive Navigation LLC is looking to raise $4 million in new funding, according to a recent filing with the U.S. Securities and Exchange Commission.
Proscia Inc., creators of AI-powered digital pathology software, today announced it has signed a first-of-its-kind agreement with one of the largest dermatopathology labs in the country, signaling Proscia’s entrance into the dermatopathology market and ushering in a new era of digital and computational pathology applied to dermatology.
Pharma major Lupin announced the launch of its Tydemy™ Tablets (Drospirenone, Ethinyl Estradiol, Levomefolate Calcium, 3mg/0.03mg/0.451mg and Levomefolate Calcium, 0.451mg) having received an approval from the United States Food and Drug Administration (FDA) earlier.
